Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept.
Etanercept-induced organizing pneumonia (OP) has not been reported in Japan. We describe the case of a rheumatoid arthritis patient who developed OP during etanercept treatment and discuss the possible mechanisms underlying the development of etanercept-induced OP and the existence of factors that predispose Japanese patients to drug-induced OP.
Sakaida
Hiroyuki
H
Odoriba Sakaida Clinic, 8-2-1 Gumisawa-cho, Totsuka-ku, Yokohama, 245-0061, Japan. hsakaida3365@jcom.home.ne.jp
Komase
Yuko
Y
Takemura
Tamiko
T
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018549:Cryptogenic Organizing Pneumonia / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D003545:Cysteine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D013902:Radiography, Thoracic; D018124:Receptors, Tumor Necrosis Factor; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D003545:Cysteine; D000068800:Etanercept; C026535:bucillamine; D008727:Methotrexate